Rxsight Inc Asset Resilience Ratio
Rxsight Inc asset resilience ratio. Rxsight Inc (RXST) has an Asset Resilience Ratio of 55.41% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RXST cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Rxsight Inc (2019–2025)
Asset resilience ratio of Rxsight Inc from 2019 to 2025. This chart shows how Rxsight Inc's Asset Resilience Ratio has changed over time. Read RXST liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Rxsight Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Rxsight Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $195.45 Million | 55.41% |
| Total Liquid Assets | $195.45 Million | 55.41% |
Asset Resilience Insights
- Very High Liquidity: Rxsight Inc maintains exceptional liquid asset reserves at 55.41% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rxsight Inc Industry Peers by Asset Resilience Ratio
Compare Rxsight Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Rxsight Inc Asset Resilience Ratio by Year (2019–2025)
Rxsight Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Rxsight Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 66.76% | $208.18 Million | $311.81 Million | -2.46pp |
| 2024-12-31 | 69.22% | $220.52 Million | $318.56 Million | +4.86pp |
| 2023-12-31 | 64.36% | $117.49 Million | $182.55 Million | +1.78pp |
| 2022-12-31 | 62.58% | $93.97 Million | $150.16 Million | -7.46pp |
| 2021-12-31 | 70.03% | $134.97 Million | $192.72 Million | +15.42pp |
| 2020-12-31 | 54.61% | $54.98 Million | $100.68 Million | -11.23pp |
| 2019-12-31 | 65.84% | $72.71 Million | $110.43 Million | -- |
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more